Background Lithium is a first-line treatment in bipolar disorder, but individual response is
variable. Previous studies have suggested that lithium response is a heritable trait. However, …

Bipolar disorder (BD) is a genetically complex mental illness characterized by severe
oscillations of mood and behaviour. Genome-wide association studies (GWAS) have identified …

BackgroundLittle is known about the impact of insulin resistance on bipolar disorder.AimsTo
examine the relationships between insulin resistance, type 2 diabetes and clinical course …

Importance Lithium is a first-line mood stabilizer for the treatment of bipolar affective disorder
(BPAD). However, the efficacy of lithium varies widely, with a nonresponse rate of up to 30%…

Lithium is a first-line medication for bipolar disorder (BD), but only one in three patients
respond optimally to the drug. Since evidence shows a strong clinical and genetic overlap …

Lithium is the gold standard therapy for Bipolar Disorder (BD) but its effectiveness differs
widely between individuals. The molecular mechanisms underlying treatment response …

Lithium is regarded as the first-line treatment for bipolar disorder (BD), a severe and disabling
mental health disorder that affects about 1% of the population worldwide. Nevertheless, …

Background Response to lithium in patients with bipolar disorder is associated with clinical
and transdiagnostic genetic factors. The predictive combination of these variables might help …

Bipolar affective disorder (BD) is a severe psychiatric illness, for which lithium (Li) is the
gold standard for acute and maintenance therapies. The therapeutic response to Li in BD is …

Bipolar disorder (BD) is a common, highly heritable neuropsychiatric disease characterized
by recurrent episodes of mania and depression. Lithium is the best-established long-term …